Compare ATRC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | ABCL |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2005 | 2020 |
| Metric | ATRC | ABCL |
|---|---|---|
| Price | $28.41 | $5.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $51.17 | $8.40 |
| AVG Volume (30 Days) | 692.6K | ★ 7.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.74 | 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,630,000.00 | $75,128,000.00 |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | $12.21 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.40 | ★ 160.56 |
| 52 Week Low | $25.36 | $2.75 |
| 52 Week High | $43.18 | $6.79 |
| Indicator | ATRC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 51.15 |
| Support Level | $28.03 | $3.42 |
| Resistance Level | $30.49 | $5.63 |
| Average True Range (ATR) | 1.20 | 0.55 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 70.72 | 13.48 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.